Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846912 | 1.00 | KMT2A (0.50) | KMT2APOLBL3MBTL1NOD1FOLH1 | |
| SCHEMBL22967338 | 1.00 | KMT2A (0.50) | KMT2APOLBL3MBTL1NOD1FOLH1 | |
| SCHEMBL22967364 | 1.00 | KMT2A (0.50) | KMT2APOLBL3MBTL1NOD1FOLH1 | |
| SCHEMBL24846081 | 1.00 | KMT2A (0.50) | KMT2APOLBL3MBTL1NOD1FOLH1 | |
| SCHEMBL22967349 | 0.93 | KMT2A (0.44) | KMT2APOLBL3MBTL1NOD1FOLH1 | |
| SCHEMBL25485995 | 0.85 | KMT2A (0.38) | KMT2APOLBL3MBTL1NOD1FOLH1 | |
| SCHEMBL677269 | 0.85 | TSHR (0.38) | POLBL3MBTL1ALDH1A1 | |
| SCHEMBL677268 | 0.85 | TSHR (0.38) | POLBL3MBTL1ALDH1A1 | |
| SCHEMBL23446467 | 0.84 | L3MBTL1 (0.53) | KMT2APOLBL3MBTL1NOD1KDM4E | |
| SCHEMBL24846075 | 0.83 | L3MBTL1 (0.42) | KMT2APOLBL3MBTL1NOD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000997-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | L.E.A.F. HOLDINGS GROUP LLC | 2023-01-05 | — | — | US | disclosed |
| WO-2021026310-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | L.E.A.F. HOLDINGS GROUP LLC (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000997-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | FPGS, ALG1, PHOSPHO1 | KMT2A 1053/4885POLB 760/4885L3MBTL1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.